Trial · NCT01822587

Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving

NCT01822587, Phase 2, Completed, Medical University of South Carolina; results first posted 2019-12-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving. Trials, record NCT01822587. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01822587

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving
NCT number: NCT01822587
Status: Completed
Phases: Phase 2
Enrollment: 181 participants, actual
Lead sponsor: Medical University of South Carolina
Conditions: Cocaine Addiction
Interventions: Propranolol, 40 mg, Propranolol, 80 mg, Placebo
First posted: 2013-04-02
Last updated: 2019-12-26
Results first posted: 2019-12-17

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Cocaine Use	Evaluated at Weeks 1, 3 and 6	Timeline of cocaine use throughout the duration of the study (in dollar amounts)
Primary	Change in Craving Score	Single-Item Craving Scores are collected at all Retrieval Extinction Sessions (medication days), as well as all Phase Two Test Sessions (weeks 1,3 and 6).	The participant is asked, "What is the level of craving you are experiencing on a scale or 0 to 100, with 0 representing no craving and 100 extreme craving"?
Primary	Days of Abstinence	Week 1, Week 3, and Week 6	How many days the participants used cocaine versus how many days of abstinence they were able to achieve.
Primary	Average Peak Craving Score	Day 2, Week 1, Week 3, and Week 6	Peak Craving Response from Session Baseline- peak craving is measured by a scale with a score of 0 (no craving) -100 (maximum craving).
Primary	Use Days	Week 1, Week 3, Week 6	Mean Days of Cocaine Use

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Cocaine Use	Evaluated at Weeks 1, 3 and 6	Dollar amounts of cocaine use	MEAN
PRIMARY	Change in Craving Score	Single-Item Craving Scores are collected at all Retrieval Extinction Sessions (medication days), as well as all Phase Two Test Sessions (weeks 1,3 and 6).	score on a scale	MEAN
PRIMARY	Days of Abstinence	Week 1, Week 3, and Week 6	Days	NUMBER
PRIMARY	Average Peak Craving Score	Day 2, Week 1, Week 3, and Week 6	score on a scale	MEAN
PRIMARY	Use Days	Week 1, Week 3, Week 6	Days	MEAN

Source ClinicalTrials.gov

Results by group51

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Cocaine Use	Placebo	Week 1	58.9	Standard Error 31.95	Dollar amounts of cocaine use
Cocaine Use	Propranolol 40mg	Week 1	71.57	Standard Error 31.63	Dollar amounts of cocaine use
Cocaine Use	Propranolol, 80mg	Week 1	69.63	Standard Error 30.74	Dollar amounts of cocaine use
Cocaine Use	Placebo	Week 3	121.25	Standard Error 32.67	Dollar amounts of cocaine use
Cocaine Use	Propranolol 40mg	Week 3	177.67	Standard Error 32.34	Dollar amounts of cocaine use
Cocaine Use	Propranolol, 80mg	Week 3	135.81	Standard Error 31.93	Dollar amounts of cocaine use
Cocaine Use	Placebo	Week 6	186.57	Standard Error 33.21	Dollar amounts of cocaine use
Cocaine Use	Propranolol 40mg	Week 6	198.9	Standard Error 32.85	Dollar amounts of cocaine use
Cocaine Use	Propranolol, 80mg	Week 6	242.79	Standard Error 32.47	Dollar amounts of cocaine use
Change in Craving Score	Placebo	Day 2	25.6	Standard Error 3.0	score on a scale

1 to 10 of 51Source ClinicalTrials.gov

See all 51 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	59
Overall Study	STARTED	Propranolol 40mg	60
Overall Study	STARTED	Propranolol, 80mg	62
Overall Study	COMPLETED	Placebo	43
Overall Study	COMPLETED	Propranolol 40mg	45
Overall Study	COMPLETED	Propranolol, 80mg	44
Overall Study	NOT COMPLETED	Placebo	16
Overall Study	NOT COMPLETED	Propranolol 40mg	15
Overall Study	NOT COMPLETED	Propranolol, 80mg	18

Source ClinicalTrials.gov

Adverse events3

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Participant Hospitalization	Psychiatric disorders	Placebo	0	59	0
other	Participant Hospitalization	Psychiatric disorders	Propranolol 40mg	1	1	1
other	Participant Hospitalization	Psychiatric disorders	Propranolol, 80mg	0	62	0

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	59
Total, all-cause mortality	Propranolol 40mg	0	60
Total, all-cause mortality	Propranolol, 80mg	0	62
Total, other adverse events	Placebo	0	59
Total, other adverse events	Propranolol 40mg	1	60
Total, other adverse events	Propranolol, 80mg	0	62
Total, serious adverse events	Placebo	0	59
Total, serious adverse events	Propranolol 40mg	0	60
Total, serious adverse events	Propranolol, 80mg	0	62

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01822587

GET https://conductscience.org/api/trials/v1/NCT01822587/results?page=2

API reference For AI assistants